Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Change in Receivables (2018 - 2023)

Abvc Biopharma (ABVC) has disclosed Change in Receivables for 8 consecutive years, with -$37292.0 as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Change in Receivables fell 106.4% year-over-year to -$37292.0, compared with a TTM value of -$228557.0 through Dec 2023, down 137.21%, and an annual FY2023 reading of -$228557.0, down 137.21% over the prior year.
  • Change in Receivables was -$37292.0 for Q4 2023 at Abvc Biopharma, down from -$9700.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $582257.0 in Q4 2022 and bottomed at -$170570.0 in Q4 2021.
  • Average Change in Receivables over 5 years is $25186.8, with a median of -$4233.5 recorded in 2019.
  • The sharpest move saw Change in Receivables skyrocketed 1961.93% in 2019, then plummeted 22543.37% in 2023.
  • Year by year, Change in Receivables stood at $144704.0 in 2019, then plummeted by 69.86% to $43614.0 in 2020, then plummeted by 491.09% to -$170570.0 in 2021, then skyrocketed by 441.36% to $582257.0 in 2022, then plummeted by 106.4% to -$37292.0 in 2023.
  • Business Quant data shows Change in Receivables for ABVC at -$37292.0 in Q4 2023, -$9700.0 in Q3 2023, and -$68226.0 in Q2 2023.